Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Revenue News
Ophthalmic Company Revenue Up 6.3 Percent as Four Companies Report Record-High Quarters
Ophthalmic manufacturer revenue in Q3-2024 totaled $11.8 billion. Revenue increased 6.3 percent from the same quarter in 2023 and increased 0.8 percent from Q2-2024. The total includes Market Scope...
Q3-2024 Ophthalmic Revenue Roundup for Immunocore, Harrow, Tarsus, Lumibird, and Ocular Therapeutix
UK-headquartered Immunocore reported Nov. 6 that its Q3-2024 net revenue from Kimmtrak (tebentafusp) was $80.2 million, a 28 percent increase over $62.6 million in Q3-2023. Regionally, Kimmtrak net...
Q3-2024 Ophthalmic Revenue Roundup for Alcon, Hoya, RxSight, Sight Sciences, and Iridex
Alcon reported Nov. 12 that its Q3-2024 net sales totaled $2.4 billion, a 6 percent increase over $2.3 billion in Q3-2023. Surgical net sales for implantables, consumables, and equipment/other were...
Q3-2024 Ophthalmic Revenue Roundup for AbbVie, Apellis, Glaukos, STAAR, and Lensar
AbbVie, of North Chicago, Illinois, reported Oct. 30 that its Q3-2024 eye care net revenue was $525 million, a 13.5 percent decline (-11.2 percent cc) from $605 million in Q3-2023. Restasis revenue...
Q3-2024 Ophthalmic Revenue Roundup for Regeneron, Bausch + Lomb, and Novartis
Regeneron of Tarrytown, New York, reported Oct. 31 that its Q3-2024 US revenue for Eylea (aflibercept) 2 mg and Eylea HD (a higher dose of aflibercept at 8 mg) was $1.54 billion, a 3 percent increa...
Q3-2024 Ophthalmic Revenue Roundup for Roche and J&J Vision
Swiss company Roche reported Oct. 23 that Q3-2024 Vabysmo sales were CHF 1 billion ($1.15 billion, converted on Oct. 23, 2024), a 59 percent increase over CHF 656 million in Q3-2023. The company sa...
Ophthalmic Company Revenue Up 2.6 Percent; Several Public Firms Report Record-High Quarters
Ophthalmic manufacturer revenue in Q2-2024 totaled $11.7 billion. Revenue increased 2.6 percent from the same quarter in 2023 and increased 5.9 percent from Q1-2024. The total includes Market Scope...
Alcon Reports Q2-2024 Net Sales of $2.5 Billion
Alcon reported Aug. 20 that its Q2-2024 net sales totaled $2.5 billion, a record quarter for the company and a 3 percent increase (+6 percent cc) over $2.4 billion in Q2-2023. Surgical net sales fo...
European Five Market Expected to Grow, Despite MDR Delays
Device makers’ added costs for compliance with the new Medical Device Regulation (MDR) in the European Union (EU) will likely affect the mix of ophthalmic products and companies in the region. Howe...
Q2-2024 Ophthalmic Revenue Roundup for AbbVie, Carl Zeiss Meditec, Amgen, STAAR, Astellas, Immunocore, Tarsus, Biogen, Lensar, and Iridex
AbbVie, of North Chicago, Illinois, reported July 25 that Q2-2024 net revenue for its eye care products totaled $533 million, a 13.3 percent decline (-10.9 percent cc) from $617 million in Q2-2023....
Q2-2024 Ophthalmic Revenue Roundup for Hoya, Harrow, RxSight, Sight Sciences, Ocular Therapeutix, and EyePoint
Japan-based Hoya Corporation announced Aug. 1 that its medical care segment (IOLs, endoscopes, artificial bone) had revenue for the quarter ending June 30, 2024—the first quarter of its fiscal year...
Q2-2024 Ophthalmic Revenue Roundup for Regeneron, Roche, Bausch + Lomb, Novartis, and Four Others
Regeneron, of Tarrytown, New York, reported Aug. 1 that its Q2-2024 US revenue for Eylea was $1.53 billion, a 2 percent increase from $1.5 billion in Q2-2023. Eylea HD accounted for $304 million of...
J&J Vision Generates Q2-2024 Surgical Revenue of $367 Million
J&J Vision’s Q2-2024 global surgical revenue totaled $367 million, a 0.5 percent decrease (1.2 percent increase in constant currency) from $369 million in Q2-2023, parent Johnson & Johnson, of New ...
Ophthalmic Company Revenue Totals $11 Billion, a Drop of 0.2 Percent, in Q1-2024
Ophthalmic manufacturer revenue in Q1-2024 totaled $11.0 billion. Revenue decreased 0.2 percent from the same quarter in 2023 and dropped 1.7 percent from Q4-2023. The total includes Market Scope e...
Q1-2024 Ophthalmic Revenue Roundup for Amgen, Hoya, and Immunocore
Amgen, of Thousand Oaks, California, reported May 2 that its Q1-2024 revenue from Tepezza was $424 million. The total consisted of $419 million in the US and $5 million outside the US. The company ...
Q1-2024 Ophthalmic Revenue Roundup for AbbVie, Iridex, and Biogen
AbbVie, of North Chicago, Illinois, reported April 26 that its Q1-2024 eye care net revenue totaled $538 million, an 11.7 percent decline (-10.4 percent cc) from $608 million in Q1-2023. Restasis r...
Q1-2024 Ophthalmic Revenue Roundup for Alcon, Carl Zeiss Meditec, and Harrow
Alcon reported May 13 that its Q1-2024 net sales were $2.4 billion, a 5 percent increase (+7 percent cc) over $2.3 billion in Q1-2023. Surgical net sales totaled $1.34 billion, consisting of $433 m...
Q1-2024 Ophthalmic Revenue Roundup for Apellis, STAAR, RxSight, Tarsus, Sight Sciences, and Three Others
Apellis Pharmaceuticals, of Waltham, Massachusetts, reported May 7 that its Q1-2024 US net product revenue for Syfovre was $137.5 million, compared with $18.4 million in Q1-2023. Syfovre gained US ...
Q1-2024 Ophthalmic Revenue Roundup for Bausch + Lomb, Glaukos, and Lumibird
Bausch + Lomb reported May 1 that its Q1-2024 revenue was $1.1 billion, an 18 percent increase (+20 percent cc) over $931 million in Q1-2023. Vision Care segment revenue in Q1-2024 was $635 million...
Q1-2024 Ophthalmic Revenue Roundup for Roche, Novartis, and Nicox
Swiss company Roche reported April 24 that Vabysmo sales in Q1-2024 were CHF 847 million ($926.5 million, calculated April 24, 2024), up from CHF 432 million (US $487 million) in Q1-2023. Vabysmo r...
J&J Vision Reports Q1-2024 Surgical Revenue of $348 Million
J&J Vision’s Q1-2024 global surgical revenue totaled $348 million, up 0.3 percent (+1.1 percent cc) over $347 million in Q1-2023, parent Johnson & Johnson, of New Brunswick, New Jersey, reported Ap...
2023 Ophthalmic Revenue Roundup for Iridex and NovaBay
Iridex, of Mountain View, California, reported March 26 that its 2023 revenue was $51.9 million, a 9 percent decrease from $57 million in 2022. Cyclo G6 product revenue was $13.4 million, a 9 perce...
2023 Ophthalmic Revenue Roundup for Harrow, Alimera Sciences, and EyePoint
Nashville, Tennessee-based Harrow reported March 19 that its 2023 revenue was $130.2 million, a 47 percent increase over $88.6 million in 2022. The company generated record quarterly revenue in Q4-...
Ophthalmic Company Revenue in Q4-2023 Rises 0.4 Percent
Ophthalmic manufacturer revenue in Q4-2023 totaled $11.2 billion. Revenue increased 0.4 percent from the same quarter in 2022 and increased 1.0 percent from Q3-2023. The total includes Market Scope...
2023 Ophthalmic Revenue Roundup for Sight Sciences and Ocular Therapeutix
Sight Sciences reported March 7 that it generated 2023 total revenue of $81.1 million, an increase of 14 percent over $71.3 million in 2022. Surgical glaucoma revenue in 2023 was $74.3 million, a 1...
2023 Ophthalmic Revenue Roundup for Immunocore, RxSight, Lensar, and Biogen
UK-headquartered Immunocore reported Feb. 28 that its 2023 net product revenue from Kimmtrak (tebentafusp) was $238.7 million, a 70 percent increase over $140.7 million in 2022. The 2023 total was ...
2023 Ophthalmic Revenue Roundup for Alcon, Bausch + Lomb, STAAR, Glaukos, Apellis, and Tarsus
Alcon reported Feb. 27 that its full year 2023 net sales totaled $9.4 billion, an 8 percent increase (+10 percent cc) over $8.7 billion in 2022. Q4-2023 sales were $2.3 billion, an 8 percent increa...
Ophthalmic Quarterly Revenue Roundup for Carl Zeiss Meditec and Hoya
Carl Zeiss Meditec reported Feb. 9 that ophthalmology revenue for the last three months of 2023, its first quarter of fiscal year 2023/2024, totaled €351.1 million ($378.5 million, converted Feb. 9...
2023 Ophthalmic Revenue Roundup for Regeneron, AbbVie, Amgen, and Astellas
Regeneron, of Tarrytown, New York, reported Feb. 2 that its 2023 US revenue for Eylea 2 mg (aflibercept 2 mg) and Eylea HD (aflibercept 8 mg) totaled $5.9 billion, a 6 percent decline from $6.3 bil...
2023 Ophthalmic Revenue Roundup for Roche, Novartis, and Lumibird
Swiss company Roche reported Feb. 1 that global sales of Vabysmo for 2023 were CHF 2.36 billion ($2.78 billion, converted Feb. 1, 2024), a 299 percent increase (+324 percent cc) over CHF 591 millio...
2023 Ophthalmic Revenue Roundup for J&J Vision and Nicox
Johnson & Johnson reported Jan. 23 that its full year 2023 global surgical vision revenue was $1.37 billion, a 4.9 percent increase (+5.8 percent cc) over $1.31 billion in 2022. Revenue was down 1....
Carl Zeiss Meditec Reports Annual Ophthalmic Revenue of $1.67 Billion
Carl Zeiss Meditec reported Dec. 12 that ophthalmology revenue for is full fiscal year 2022/2023, which ended Sept. 30, was €1.58 billion ($1.67 billion, converted Sept. 30), a 7.3 percent increase...
Ophthalmic Company Revenue Increases 3.4 Percent in Third Quarter of 2023
Ophthalmic manufacturer revenue in Q3-2023 totaled $11.1 billion. Revenue increased 3.4 percent from the same quarter in 2022 and decreased 2.7 percent from Q2-2023. The total includes Market Scope...
Q3-2023 Ophthalmic Revenue Roundup for Alcon, Iridex, and Lensar
Alcon reported Nov. 14 that its Q3-2023 net sales totaled $2.3 billion, an 8 percent increase (+9 percent cc) over $2.1 billion in Q3-2022. Surgical net sales for implantables, consumables, and equ...
Q3-2023 Ophthalmic Revenue Roundup for Immunocore, Harrow, RxSight, and Three Others
UK-headquartered Immunocore reported Nov. 7 that its Q3-2023 net revenue from Kimmtrak (tebentafusp) was £49.7 million ($60.7 million, converted at a rate of £1.00 to $1.2214), an increase of 9 per...
Q3-2023 Ophthalmic Revenue Roundup for Hoya, Lumibird, Sight Sciences, and Ocular Therapeutix
Japan-based Hoya Corporation reported Oct. 31 that its medical segment (IOLs, endoscopes, and artificial bone) generated revenue for the third quarter of 2023—its fiscal year Q2-2023—of ¥33.5 billi...
Q3-2023 Ophthalmic Revenue Roundup for Regeneron, Bausch + Lomb, AbbVie, and Five Others
Regeneron of Tarrytown, New York, reported Nov. 2 that its Q3-2023 US revenue for Eylea (aflibercept) 2 mg and Eylea HD (a higher dose of aflibercept at 8 mg) was $1.49 billion, with Eylea HD accou...
Q3-2023 Ophthalmic Revenue Roundup for Roche, Novartis, J&J Vision, and Nicox
Swiss company Roche reported Oct. 19 that Q3-2023 Vabysmo sales were CHF 656 million ($732 million, converted Oct. 19), a 309 percent increase over CHF 173 million in Q3-2022. Vabysmo was approved ...
Ophthalmic Company Revenue in Q2-2023 Rises 1.5 Percent
Ophthalmic manufacturer revenue in Q2-2023 totaled $11.4 billion. Most public companies reported above-average revenue in Q2-2023 compared with the past three years, while four public companies had...
Viatris Reports Q2-2023 Tyrvaya Net Sales of $10.2 Million
Viatris, of Pittsburgh, reported Aug. 7 that its Tyrvaya nasal spray for dry eye accounted for net sales of $10.2 million in Q2-2023. The prescription treatment posted net sales of $6.3 million in ...
Q2-2023 Ophthalmic Revenue Roundup for Horizon and Biogen
Horizon Therapeutics, of Dublin, Ireland, reported Aug. 8 that its Q2-2023 Tepezza net sales totaled $446 million, a 7 percent decrease from $479.8 million in Q2-2022. The company said expansion of...
Q2-2023 Ophthalmic Revenue Roundup for AbbVie, Carl Zeiss Meditec, Alimera
AbbVie, of North Chicago, Illinois, reported July 27 that Q2-2023 net revenue for its eye care products totaled $617 million, a 13.9 percent decline from $717 million in Q2-2022. Restasis revenue w...
Q2-2023 Ophthalmic Revenue Roundup for Alcon, Immunocore, Harrow, and Two Others
Alcon reported Aug. 15 that its Q2-2023 net sales totaled $2.4 billion, a 9 percent increase (+12 percent cc) over $2.2 billion in Q2-2022. Surgical net sales for implantables, consumables, and equ...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.